A phase I, single center, randomized, double blind, placebo controlled, single ascending dose study to investigate the safety, tolerability, and pharmacokinetics of GRC 17536, a new TRPA1 antagonist, in healthy volunteers.
Completed
- Conditions
- Astma, COPD, hoesten, chronische pijnAsthmaCOPD
- Registration Number
- NL-OMON36129
- Lead Sponsor
- Glenmark Pharmaceuticals SA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 76
Inclusion Criteria
18 - 45 years of age, male, BMI 18.0 - 28.0 kg/m2, no smokers.
Exclusion Criteria
Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of TRPA1 antagonism in GRC 17536 for asthma and COPD treatment?
How does GRC 17536 compare to standard-of-care bronchodilators in preclinical asthma/COPD models?
Which biomarkers correlate with TRPA1 inhibitor efficacy in chronic cough and neuropathic pain conditions?
What adverse event profiles are observed in TRPA1 antagonist clinical trials for respiratory diseases?
Are there combination therapies involving TRPA1 inhibitors like GRC 17536 for refractory asthma or COPD?